What Diascan Treats: Main Uses and Benefits

Diascan is used by patients to support the management of conditions that involve routine blood glucose measurement. It is indicated for the self-testing and professional monitoring of blood glucose levels in whole blood, and it is a tool used in the management of blood glucose levels for individuals with diabetes mellitus. Indications include testing in individuals with Type 1 diabetes, Type 2 diabetes, and gestational diabetes.

Common clinical scenarios involve frequent at-home monitoring to guide daily diet, exercise, and medication adjustments, and it is also utilized by healthcare professionals in point-of-care settings. The use of the device provides patients with readily available information that may assist in managing fluctuations in their blood glucose levels. The device's purpose is to provide data intended to assist in managing blood glucose within a target range.

“Self-monitoring of blood glucose can be a supportive component in the care of individuals with diabetes mellitus.”

---

Quick Fact: Relief for Monitoring Uncertainty

Who Can and Cannot Use Diascan?

Diascan (Gadodiamide), a specialized MRI contrast agent, has specific eligibility rules defined by regulatory authorities, primarily centered on the patient's renal function and hypersensitivity history.

Absolute Contraindications

Use of Diascan is contraindicated (must not be used) in the following populations as stated in official labeling:

• Severe Renal Impairment: Patients with chronic, severe kidney disease (Glomerular Filtration Rate, or GFR, less than 30 mL/min/1.73m²), or those with Acute Kidney Injury (AKI). This restriction is critical due to the risk of Nephrogenic Systemic Fibrosis (NSF).
• Hypersensitivity: Patients with a known history of severe allergic or anaphylactic reactions to Gadodiamide or any excipient in the formulation.

Restricted and Age-Based Use

The product is generally reserved for use in Adults and Older Pediatric Patients (e.g., 2 years and older) who possess normal renal function. Caution is required for older adults (e.g., 60 years and above), who must be screened for reduced kidney function prior to administration.

For patients with Moderate Renal Impairment (GFR 30–59 mL/min/1.73m²), use is restricted to a single, low dose.

Regulatory agencies advise that the drug be used only if essential during pregnancy due to potential fetal exposure. In several regions, the use of this specific agent has been suspended by regulatory bodies.

The official regulatory documents for Diascan (Gadodiamide) provide specific information regarding its interaction profile, which is largely characterized by the absence of formally documented drug-drug interactions.

Drug-Drug Interaction Profile

The prescribing information states that specific pharmacokinetic or pharmacodynamic drug interaction studies have not been conducted with Gadodiamide. Consequently, the regulatory label does not list any specific medicinal products as contraindicated combinations or as substances that alter the drug's metabolic pathway, such as through the cytochrome P450 enzyme system. Gadodiamide is primarily eliminated from the body via glomerular filtration.

Drug–Product Interference and Timing Rules

A mandatory procedural constraint is documented regarding the drug’s potential to interfere with certain laboratory tests. Gadodiamide may chemically interfere with complexometric (colorimetric) methods used to measure serum calcium concentration, leading to inaccurate test results. To avoid this drug–product interference, a timing separation rule is required: the affected serum calcium measurement should not be performed for 12 to 24 hours following Diascan administration.

Exposure and Population Constraints

The official documentation emphasizes that the risk associated with drug elimination is heightened in certain populations. Due to its renal clearance, caution and pre-administration evaluation of renal function are required, especially for patients with severe renal impairment. Furthermore, a regulatory restriction applies to total systemic exposure, advising that repeated dosing of Diascan or co-administration with other Gadolinium-Based Contrast Agents should be carefully considered to minimize cumulative exposure.

Physical Mechanism: Paramagnetic Field Enhancement

Diascan functions as a paramagnetic agent, an interaction type driven by the Gd^3+ ion, which possesses seven unpaired electrons. This physical presence does not modulate biological pathways; instead, it generates a strong local magnetic field in the extracellular fluid. This field acts on nearby water protons (the primary biological target), accelerating their longitudinal ( T1) relaxation rate and thereby shortening the T1 relaxation time . The system-level consequence is the creation of a high-intensity signal (brightness) on T1-weighted magnetic resonance images.

Distribution and Vascular Permeability Dependence

The agent is a water-soluble complex that distributes through the vascular and interstitial compartments. Its systemic activity is restricted by cellular barriers, notably the Blood-Brain Barrier (BBB). The key mechanistic cascade involves passive extravasation: the agent leaks out of the vasculature only in areas where vascular integrity is compromised. This physical consequence of restricted distribution provides information related to the integrity of the vascular barrier itself.

How Diascan Is Used: Official Administration Guidelines

Diascan is a specialized diagnostic agent used exclusively to enhance image clarity during Magnetic Resonance Imaging (MRI) procedures. Its application follows strict protocols, focusing solely on the mechanics of its professional delivery.

Administration Scope

The product is provided as a sterile solution for injection and is administered only through the intravenous (IV) route.

Feature	Official Protocol
Dosing Schedule	The standard adult dose is 0.1 mmol of Gadodiamide per kilogram (kg) of patient body weight (equivalent to 0.2 mL/kg for the 0.5 mmol/mL solution).
Frequency	Use is limited to a single administration per diagnostic imaging session. The product is not intended for repeated or cyclical use for the same procedure.
Age-Group Rules	The official dose of 0.1 mmol/kg applies to both adults and pediatric patients aged 2 years and older.
Renal Considerations	Re-administration of the agent requires sufficient time for elimination to pass between doses; professional guidelines emphasize careful consideration of use in individuals with existing kidney issues.

Procedural Structure

The correct use of Diascan is a professional procedural sequence performed by trained personnel. The calculated dose is administered as an intravenous bolus injection—a rapid delivery into the vein. This injection must be immediately followed by a saline flush (a small volume of 0.9% sodium chloride solution) to ensure the full quantity of the contrast agent reaches the systemic circulation for the imaging procedure. The solution must be inspected for clarity prior to use, and any unused portion remaining in the container must be discarded after the procedure.

This structure defines the precise steps necessary for administering Diascan to achieve standardized contrast enhancement during an MRI examination.

Research evidence / Overview of studies for Diascan

Evidence for Use in Central Nervous System (CNS) Imaging

The research into Diascan's role in visualizing the brain and spinal cord primarily involves short-term, randomized, controlled trials. These trials were structured to examine how image clarity, technically measured as Contrast-to-Noise Ratio (CNR), was evaluated after the injection compared to scans taken without the contrast agent. Studies monitored how the contrast agent was observed in adult patients with known or suspected conditions, such as brain or spinal tumors, and in specific pediatric populations.

Findings describe patterns observed in the studies where the use of the agent was associated with measurements of increased CNR and generally assessments often described patterns related to the visualization of abnormal tissues by the assessing radiologists. However, the existing research is limited primarily to the short-term period—the time during and immediately after the MRI scan. Long-term effects are not fully established, meaning the research does not typically follow patients for several years to track whether the visualization findings ultimately relate to improved patient outcomes or survival.

Evidence for Visualization in General Body Regions

Research has also explored Diascan's use to aid in the visualization of abnormalities in various extracranial body regions, including the abdomen, pelvis, and soft tissues. This evidence comes from both controlled trials and large observational studies. These studies focused on imaging endpoints such as the detection rate of lesions and the clarity of lesion boundaries, and what was evaluated regarding the overall diagnostic information available to the clinician.

Data show patterns related to enhanced visual characteristics for specific lesions when the agent was used, compared to unenhanced images. Because this research covers many different organs and disease states, the evidence quality varies across studies and the findings were mixed depending on the specific body part or condition being examined. The studies primarily describe the short-term image findings, and there is a general lack of evidence describing how these imaging changes relate to long-term patient outcomes, such as recovery or functional improvement.

Key Studies & References

1. Diagnostic efficacy of gadodiamide for detection of coronary artery disease by magnetic resonance perfusion imaging: a systematic review

Common questions about Diascan (FAQ)

---

Q: Are there any known drug-drug interactions with Diascan?

Official regulatory documents indicate that specific studies to look for drug-drug interactions with Diascan have not been performed. Consequently, the prescribing information does not currently list any specific medicines as combinations that are contraindicated or known to interfere with its action.

---

Q: What kind of laboratory tests can be affected by the injection?

Diascan may interfere with certain laboratory methods, specifically those used to measure serum calcium concentration in the blood. To help prevent inaccurate results, regulatory documents state that the affected test should not be performed for 12 to 24 hours following administration of Diascan.

---

Q: How does Diascan work to improve the MRI image?

Diascan functions as a paramagnetic agent, a substance that interacts with magnetic fields. The active ingredient creates a strong magnetic effect that speeds up the relaxation rate of water molecules in the body. This is associated with a higher signal intensity, which helps certain tissues or abnormal structures appear clearer on the MRI images.

---

Q: Can Diascan be used for patients under 2 years old?

According to the official product information, the safety and effectiveness of Diascan have not been established in pediatric patients who are younger than two years of age.

---

Q: How long does the contrast effect last on the MRI scan?

The contrast effect is designed to occur during the diagnostic procedure itself. Official administration guidelines indicate that the necessary MRI imaging should be completed within 1 hour after the contrast agent has been administered.

---

Q: What is the chemical name for the excipient/non-active ingredients?

The product's core is the active ingredient, Gadodiamide. It also contains inactive ingredients, or excipients, which are listed in the regulatory documents as Calciodiamide Trisodium, Trisodium Hydroxide (used to adjust the pH level), and Water for Injection.

---

Q: How is the product eliminated from the body?

Diascan is primarily eliminated from the body through the kidneys and passed out in the urine. For healthy individuals, the elimination half-life is reported to be approximately 1.3 hours, with about 95% of the dose typically cleared from the body within 24 hours.

---

Q: Is Diascan ever administered orally instead of intravenously?

The product information clearly states that Diascan is supplied as a solution for intravenous (IV) use only. It should not be administered via other routes.

How to Store and Dispose of Diascan?

The storage and disposal of Diascan (Gadodiamide injection) must strictly follow the official regulatory requirements to maintain product quality and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (or at Controlled Room Temperature). Do not freeze.
Protection	The product must be protected from light during storage.
Safety	Keep out of the sight and reach of children.
Pre-Use Rule	The solution must be visually inspected for discoloration or particulate matter before use; do not use if particles are present.

Handling and Stability

Diascan is supplied in single-dose containers and must be handled under strict stability rules. The solution must be used immediately after drawing it into a syringe. Any unused portion remaining in the vial or syringe must be discarded immediately after the procedure is complete.

Disposal

All unused product, expired medicine, and related waste materials must be disposed of in accordance with local regulations for medical or pharmaceutical waste. Do not dispose of the medicine into municipal sewerage systems or household trash.